Navigation Links
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
Date:8/25/2009

ng it, U.S. Food and Drug Administration officials stressed Monday.

But the agency does recommend that patients tell their doctor if they are having symptoms such as weakness, fatigue, fever, jaundice or brown urine. Abdominal pain, nausea, vomiting, light-colored stools, itching and loss of appetite might also signal trouble.

Monday's move follows reports of 32 cases of serious liver injury, including six cases of liver failure, between 1999 and October of 2008.

More commonly, patients reported having jaundice, weakness and abdominal pain. For 27 patients, the symptoms were severe enough to require hospitalization.

Two of the cases occurred in the United States, the rest originated overseas.

In 10 years of being on the market, this isn't a great number, Pfanner noted.

The Drug Safety Oversight Board, part of FDA's Center for Drug Evaluation and Research, first looked into the issue in April. The agency stressed that there is no established association or evidence of a cause-and-effect relationship at this time.

The FDA first approved orlistat as a prescription medicine in 1999. In 2007, it became the first nonprescription drug approved to treat obesity in American adults.

The prescription version of the drug comes in 120-milligram capsules while the over-the-counter version is available in 60-milligram pills. Both versions are designed only to be used in conjunction with a reduced-calorie, low-fat diet by overweight adults aged 18 and older.

In 2006, the consumer advocacy group Public Citizen petitioned the FDA to remove Xenical from the U.S. market, not because of liver-related issues but because it might increase the risk of aberrant crypt foci, believed to be precursors to colon cancer.

The FDA's approval of the first over-the-counter drug for weight loss came as the United States and other western nations are struggling with an unprecedented obesity epidemic.
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. FDA Investigating Safety of Asthma Drug Xolair
3. DEA Will Play Hardball in Investigating Michael Jacksons Doctors
4. Forensic Expert Investigating Chinese Drywall Issue
5. FDA Investigating Salmonella-Tainted Pistachios
6. Investigating a community where smoking rates are double the national average
7. Investigating causes of asthma attacks: New sensor system monitors environmental exposure
8. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
11. Study Finds Weight-Loss Surgery Safer Than Thought
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
(Date:9/16/2014)... Dennis Thompson HealthDay ... -- A combination drug therapy aimed at opening the ... treatment for older adults with chronic obstructive pulmonary disease ... COPD patients who received a combination of ... to die or require hospitalization because of their breathing ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... dated September 15, 2014, the Court has determined ... to the proceeding. The Order indicates that the ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Novatus, a ... a new office in London, UK, and appointed Jim ... in Europe, the expansion will allow Novatus to target ... its European customers. , “Novatus is ... and London is an ideal location to establish our ...
(Date:9/16/2014)... The child molestation victim lawyers at Estey ... who, according to case documents, were allegedly sexually abused ... San Diego. The victims were allegedly in elementary school ... of the defendant in the case remains confidential, per ... noted that no criminal charges were filed against the ...
Breaking Medicine News(10 mins):Health News: Most Treatments for Blood Clots Appear Safe, Effective 2Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:ESTEY BOMBERGER Announces $3 Million Settlement for Sexual Abuse at San Diego Private School 2
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. (CTI) ... Drug Administration (FDA) has accepted and has filed for review the ... or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User Fee ... review of the pixantrone NDA by September 4th 2009. ...
... at the time of diagnosis do not live as long ... conclusion of a new study to be published in the ... journal of the American Cancer Society. The authors of the ... marital separation may compromise an individual,s immune system and lead ...
... factor for active tuberculosis (TB) disease, according to a new ... analyzed data from nearly 17,000 individuals in Taiwan as part ... past studies have reported increased mortality among TB patients who ... effect of smoking on active TB incidence using a longitudinal ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Over one-hundred business ... , ... -- Rooted in Newtonian and quantum science, ancient spiritual and healing traditions, and clinical studies, ... book ColorAlchemy , by Jami Lin teaches people how to harness a daily color ...
... diagnosis of Idiopathic Pulmonary Fibrosis is not much better ... the survival rate is less than three years. ... that targeting of a novel gene utilizing genetic and ... mice and will be developed for future testing in ...
Cached Medicine News:Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:Smoking increases risk of developing active TB 2Health News:Smoking increases risk of developing active TB 3Health News:New technique can help diagnose mesothelioma 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 3Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 4Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2
(Date:9/16/2014)... -- On September 25 to 26, 2014, ... and manufacturing - MEDTEC China  - will mark its ... Convention Center, bringing together close to 300 leading global ... latest medical-grade raw materials, parts and processing technologies. ... free visitor pre-registration to be completed. To date, more ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... to receive formal designation as a "Promising Innovative Medicine" ... (EAMS) launched in the UK in April 2014.  A ... for early access approval under the EAMS.  ...
(Date:9/16/2014)... 2014  Synereca Pharmaceutics, Inc. (SPI), a ... drugs that restore or increase the effectiveness ... million convertible debt financing. Accele Venture Partners, ... Accele Biopharma, Inc., led the financing with ... private not-for-profit corporation focused on growing innovative ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... France, July 10 Ipsogen SA,(Alternext: ALIPS) today reported ... Therapy of Early Breast Cancer indicated for the first,time ... adjunct to the,histological grade. These new guidelines, published online ... European and US experts on,early breast cancer treatment that ...
... , KENILWORTH, N.J., July 9 Schering-Plough Corporation (NYSE: ... the company,s country operation in Japan, has received marketing ... for the treatment of bronchial asthma in adults.(1) , ... of the ASMANEX TWISTHALER in Japan," said Thomas P. ...
Cached Medicine Technology:Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 2Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 2ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 4
... System is a point-of-care system designed for ... referred to as Platelet Rich Plasma - ... a small sample of blood. The Symphony ... factors, which are found in the platelets. ...
... Dual Imaging Color Module Leica combines precision microscopy ... important and necessary patient data can be displayed ... optical platform on the Leica OH3, OHS1, MS3 ... highest brightness, contrast >300:1, true color and resolution ...
... Headlight mounted micro video camera has ... pictures in areas otherwise invisible to all ... capabilities. The system may be used for ... eliminating crowding of the sterile area and ...
... DXC-S500 consists of 2-piece body, one is CHU ... and built-in Peltier cooling devices, the other is ... monitor. CCU incorporates IEEE1394 interface for direct connection ... card slot for storing images into memory stick ...
Medicine Products: